Life Spine has earned U.S. Food and Drug Administration (FDA) clearance for its ProLift expandable spacer system.

ProLift Pivot is the latest in the company’s Micro Invasive technology portfolio. Devices in this portfolio combine full articulation capability with a patient-centered strategy to spinal fusion procedures.

The device features in-situ expansion of up to 5 mm to optimize alignment, with the ability to collapse and expand for precision repositioning. Its full articulation capability can offer optimal anterior placement, Life Spine said.

ProLift Pivot’s bulleted tip simplifies insertion and it features reduced instrument passes to boost surgical efficiency. In-situ graft delivery also seamlessly integrates the procedure.

Designed to restore normal physiologic environment, its visual and tactile confirmation mechanisms help to prevent over-distraction. The syste also touts OSSEO-LOC Surface Technology, designed to promote osseointegration and long-term implant stability.

“Receiving FDA clearance for the ProLift Pivot Expandable Spacer System is a significant milestone for Life Spine and underscores our commitment to advancing Micro Invasive technology,” said Rich Mueller, Life Spine’s chief operating officer. “This innovative system empowers surgeons with enhanced control, full articulation capabilities, while also prioritizing patient outcomes and recovery times.”

In July 2024, the company earned U.S. Food and Drug Administration (FDA) clearance to market its ARx SAI (sacral alar iliac) spinal fixation system.